October 2008
Nanogen (San Diego, Calif.) recently agreed to combine with the privately held Elitech Group (Paris, France) in a deal valued at approximately $98 million (see p. 2). The combined company will encompass the molecular, point-of-care, clinical chemistry, and microbiology diagnostics and will have estimated first-year revenues of more than $150 million. DTTR recently talked with David Ludvigson, president and chief operating officer of Nanogen, to get his view on what makes the companies a good match, what the deal means for Nanogen’s pipeline, and on the possibly intersecting futures of Nanogen’s two key markets: molecular and point-of-care diagnostics.
Subscribers: click here for the full story
Non-Subscribers: click here to subscribe
|
|
|
 Archives
|
|
October 2008 - Table of Contents
